Rosiglitazone significantly improved survival and reduced disease severity (as assessed by a modified rapid murine coma and behaviour scale (RMCBS) [21]) only in the Ang-1 sufficient mice, but not in the Ang-1del mice (Figure S4), supporting a direct role for Ang-1 in mediating, at least partly, the observed protective effects of rosiglitazone. This evidence concerns the gene ANGPT1 and Coma.